CAS: 2089288-03-7; 7-Fluoro-1-Isopropyl-3-Methyl-8-(6-(3-(Piperidin-1-yl)Propoxy)Pyridin-3-yl)-1,3-Dihydro-2H-Imidazo[4,5-C]Quinolin-2-One
- 英文名称7-Fluoro-1-Isopropyl-3-Methyl-8-(6-(3-(Piperidin-1-yl)Propoxy)Pyridin-3-yl)-1,3-Dihydro-2H-Imidazo[4,5-C]Quinolin-2-One
- 中文名称7-氟-1-异丙基-3-甲基-8-(6-(3-(哌啶-1-基)丙氧基)吡啶-3-基)-1,3-二氢-2H-咪唑并[4,5-C]喹啉-2-酮
- IUPAC名称7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
- CAS编号2089288-03-7
- MFCD编号:MFCD31619275
- FDA UNII编号:CI43QFE22O
- 分子式:C27H32FN5O2分子量:477.58
- 产品CID: 1063460
- 产品分类Inhibitors/Agonists → DNA Damage → ATM/ATR
物理性质
合成工艺路线路线简述
📜1-哌啶丙醇 在 正丁基锂,Sodium Hydride,Potassium Carbonate体系中,用 四氢呋喃,水作为反应溶剂,-78.0~64.0 °C,13.5 Kpa 条件下,反应 16.5H,获得 Azd1390
参考文献:[En] 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1-Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer[Fr] Dérivés 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1-Isopropyl-Imidazo[4,5-C]Quinoléin-2-One Utilisés En Tant Que Modulateurs Sélectifs De L'Ataxie Télangiectasie Mutée (Atm) Kinase Pour Le Traitement Du Cancer
标题:[En] 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1-Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer[Fr] Dérivés 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1-Isopropyl-Imidazo[4,5-C]Quinoléin-2-One Utilisés En Tant Que Modulateurs Sélectifs De L'Ataxie Télangiectasie Mutée (Atm) Kinase Pour Le Traitement Du Cancer
摘要:该规范通常涉及formula (I)的化合物及其药用盐,其中r1,R2,R3,R4和r5具有本规范中定义的任何含义.该规范还披露了利用formula (I)的化合物及其盐来治疗或预防atm介导的疾病,包括癌症.该规范进一步涉及包含取代咪唑并[4,5-C]喹啉-2-酮化合物及其药用盐的药物组合物;包含这些化合物和盐的试剂盒;制造这些化合物和盐的方法;以及在这种制造中有用的中间体.
海关参考信息
- 2905121000-正丙醇
2933310010-吡啶
2909199090-其他醚及其衍生物
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M. The brain- penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719.
2: Tew BY, Kalfa AJ, Yang Z, Hurth KM, Simon T, Abnoosian E, Durant ST, Hamerlik P, Salhia B. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis. Clin Cancer Res. 2023 Nov 1;29(21):4492-4503. doi: 10.1158/1078-0432.CCR-23-0290.
3: Jin MH, Oh DY. ATM in DNA repair in cancer. Pharmacol Ther. 2019 Nov;203:107391. doi: 10.1016/j.pharmthera.2019.07.002. Epub 2019 Jul 9. 30(4):e14696. doi: 10.1111/cns.14696.
合成参考文献
参考文献:10.1016/j.ejmech.2022.114196
摘要:Dou X, Sun X, Huang H, Jiang L, Jin Z, Liu Y, Zou Y, Li Z, Zhu G, Jin H, Jiao N, Zhang L, Liu Z, Zhang L. Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. European Journal of Medicinal Chemistry. 2022 Apr;233():114196. doi: 10.1016/j.ejmech.2022.114196.
参考文献:10.1093/neuonc/noaa238
摘要:Jucaite A, Stenkrona P, Cselényi Z, De Vita S, Buil-Bruna N, Varnäs K, Savage A, Varrone A, Johnström P, Schou M, Davison C, Sykes A, Pilla Reddy V, Hoch M, Vazquez-Romero A, Moein MM, Halldin C, Merchant MS, Pass M, Farde L. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study. Neuro Oncol. 2021 Apr 12;23(4):687–96.
参考文献:10.1021/acs.jmedchem.0c00766
摘要:Myers SH, Ortega JA, Cavalli A. Synthetic Lethality through the Lens of Medicinal Chemistry. J. Med. Chem. 2020 Nov 02;63(23):14151–83. doi: 10.1021/acs.jmedchem.0c00766.
📝 需求与反馈
尽可能描述清楚需求与问题信息
